Novo Nordisk
Tracked across 40 events · 409 articles · First seen Feb 02, 2025 · Last active Jul 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Sep 10, 2025 · 6 articles
Business
Impact: Novo Nordisk partnered with Emcure Pharma to expand the distribution and marketing of its weight-loss drug semaglutide in India under the brand Poviztra, aiming to reach a wider population.
Nov 10, 2025 · 6 articles
Business
Impact: Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Nov 11, 2025 · 6 articles
Regulatory
Impact: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
Business
Impact: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Tech
Impact: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
Business
Impact: Novo Nordisk is repurchasing its own B shares, which is expected to support its stock price and return value to shareholders. This action reduces the number of outstanding shares, potentially increasing earnings per share.
May 26, 2026 · 6 articles
Regulatory
Impact: Novo Nordisk is a pharmaceutical company facing multiple lawsuits alleging that its GLP-1 medications, Semaglutide and Semaglutide, caused NAION and that the company failed to adequately warn consumers about these risks. This could lead to significant financial and reputational damage.
May 22, 2026 · 7 articles
Business
Impact: Novo Nordisk partnered with Costco to expand access and sales of its GLP-1 medications, Semaglutide and Semaglutide, at a standardized discounted price, combating competition from compounding pharmacies.
Oct 03, 2025 · 8 articles
Regulatory
Impact: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Tech
Impact: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Business
Impact: Novo Nordisk is outsourcing cartridge fill-finish manufacturing services to Biopharmaceutical, which could streamline its production and supply chain.
Jun 30, 2026 · 6 articles
Tech
Impact: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
Tech
Impact: Novo Nordisk, the manufacturer of Semaglutide, is facing scrutiny due to reports of severe adverse reactions experienced by Sarah-Jayne Crawford. They have issued a statement acknowledging gallstones as a common potential adverse reaction.
Apr 13, 2026 · 6 articles
Business
Impact: Novo Nordisk has shown a more aggressive M&A approach following recent CEO transitions and has been advised on recent deals, indicating its participation in the acquisition spree.
May 01, 2026 · 6 articles
Tech
Impact: Novo Nordisk manufactures Semaglutide and Semaglutide, and the study's findings could potentially broaden the market and perceived benefits of its GLP-1 medications.
Jun 17, 2026 · 6 articles
Tech
Impact: Novo Nordisk is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
Business
Impact: Novo Nordisk is an early customer of Microsoft — Microsoft Frontier, working to identify AI tools that fit its specific business needs.
Jun 25, 2026 · 43 articles
+ 10 more events
View on Dashboard
100
Parker Waichman LLP filed lawsuits Novo NordiskParker Waichman Sues Novo...
95
Novo Nordisk produced drugsParker Waichman Sues Novo...
90
Novo Nordisk initiated share repurchaseNovo Nordisk B share repurchase
55
Novo Nordisk teased spotGLP-1 Drugs Reduce Cancer Risk
40
Microsoft — Microsoft Frontier worked with Novo NordiskMicrosoft Launches...
Hims & Hers Health
competitor
↔
Novo Nordisk
Novo Nordisk terminated its distribution partnership with Hims & Hers Health and
Hims & Hers Health
competitor
↔
Novo Nordisk
Hims & Hers Health is facing legal threats from Novo Nordisk after their brief d
ERGEN INTELLIGENCE
Track Novo Nordisk live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard